Eporise 4000 IU is a synthetic form of erythropoietin used to treat anemia caused by chronic kidney disease, chemotherapy, or HIV treatment. It stimulates red blood cell production in the bone marrow.
Eporise 4000 IU, manufactured by Emcure Pharmaceuticals, is a recombinant human erythropoietin (rHuEPO) injection used to treat anemia. It helps reduce the need for blood transfusions by promoting red blood cell (RBC) formation in patients with kidney failure, cancer, or those undergoing major surgeries.
Uses:
Anemia due to chronic kidney disease (CKD) – in dialysis and non-dialysis patients
Chemotherapy-induced anemia in cancer patients
Anemia related to HIV therapy (especially zidovudine)
Preoperative anemia before major elective surgery
Reducing need for blood transfusions in surgical patients
Anemia in premature infants (off-label in some cases)
Storage Instructions:
Store at 2°C to 8°C (refrigerator)
Do not freeze
Protect from light
Keep out of reach of children
How it Works (Mechanism of Action):
Eporise contains recombinant erythropoietin, a glycoprotein hormone that stimulates erythropoiesis (RBC production). It acts on erythroid progenitor cells in the bone marrow by:
Binding to erythropoietin receptors
Stimulating differentiation and proliferation of red blood cell precursors
CKD patients (dialysis): 50–100 IU/kg, 3 times weekly
Non-dialysis CKD: 75–150 IU/kg weekly or biweekly
Cancer-related anemia: 150 IU/kg 3 times per week or 40,000 IU weekly
Dose depends on hemoglobin levels, response, and clinical condition
Adjustments are made gradually every 2-4 weeks based on lab results
Method of Administration:
Given as subcutaneous (SC) or intravenous (IV) injection
Administered by healthcare provider or trained caregiver
Rotate injection sites to prevent irritation
Do not shake the syringe or vial
Precautions:
Monitor hemoglobin levels regularly
Avoid if hemoglobin exceeds 12 g/dL to reduce risk of thrombosis
Use with caution in patients with hypertension, cardiovascular disease, seizures
Not recommended in patients with uncontrolled hypertension
May increase tumor progression in some cancers
Drug Interactions:
No significant drug interactions reported
May interact with drugs affecting iron metabolism – iron supplementation may be required
Use with caution alongside immunosuppressants
Allergies:
Contraindicated in individuals with:
Hypersensitivity to erythropoietin or formulation components
History of PRCA after prior EPO therapy
Watch for allergic signs like rash, swelling, and difficulty breathing
Overdose Information:
Overdose may lead to polycythemia (excess red cells), hypertension, and blood clots
Requires reduction or discontinuation of dose and supportive care
No specific antidote – monitor hemoglobin and hematocrit closely
Missed Dose Instructions:
Administer the missed dose as soon as possible
Do not double dose to compensate
Resume regular schedule afterward
Additional Notes:
Iron status should be assessed; iron, folate, and B12 supplementation may be necessary
Periodic monitoring of hemoglobin, blood pressure, and electrolytes is essential
Patients should be educated on recognizing signs of blood clots and high blood pressure
Use during pregnancy only if clearly needed; avoid during breastfeeding unless directed
Product Intro:
Eporise 4000 IU, manufactured by Emcure Pharmaceuticals, is a recombinant human erythropoietin (rHuEPO) injection used to treat anemia. It helps reduce the need for blood transfusions by promoting red blood cell (RBC) formation in patients with kidney failure, cancer, or those undergoing major surgeries.
Uses:
Anemia due to chronic kidney disease (CKD) – in dialysis and non-dialysis patients
Chemotherapy-induced anemia in cancer patients
Anemia related to HIV therapy (especially zidovudine)
Preoperative anemia before major elective surgery
Reducing need for blood transfusions in surgical patients
Anemia in premature infants (off-label in some cases)
Storage Instructions:
Store at 2°C to 8°C (refrigerator)
Do not freeze
Protect from light
Keep out of reach of children
How it Works (Mechanism of Action):
Eporise contains recombinant erythropoietin, a glycoprotein hormone that stimulates erythropoiesis (RBC production). It acts on erythroid progenitor cells in the bone marrow by:
Binding to erythropoietin receptors
Stimulating differentiation and proliferation of red blood cell precursors
